Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.
The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.
The firms are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of OncoMed's therapeutic.
NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.
NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.